FDA approves new orphan drug to treat pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478599.htm

Source: Food and Drug Administration - December 22, 2015 Category: American Health Source Type: news

More News: American Health | Food and Drug Administration (FDA) | Hypertension | Lung Transplant | Transplants